757975-91-0

Upstream product

• 757976-46-8 tert-butyl [(1S)-1-({[4-(benzyloxy)phenyl]amino}methyl)propyl]carbamate 
• 757976-20-8 N-(2-oxo-6-phenyl-2H-pyran-4-yl)-L-leucine 
• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 882296-91-5 (1-{[(4-benzyloxy-phenyl)-(2-nitro-benzenesulfonyl)-amino]-methyl}-propyl)-carbamic acid tert-butyl ester 
• 313067-82-2 N-[4-(benzyloxy)phenyl]-2-nitrobenzenesulfonamide 
• 5526-38-5 4-hydroxy-6-phenyl-2H-pyran-2-one 
• 706818-02-2 4-bromo-6-phenyl-2H-pyran-2-one 

Downstream Products

• 757975-93-2 tert-butyl {4-[((2S)-2-{[N-(2-oxo-6-phenyl-2H-pyran-4-yl)-L-leucyl]amino}butyl)amino]phenoxy}acetate 
• 757976-50-4 N¹-((1S)-1-{[(4-hydroxyphenyl)amino]methyl}propyl)-N²-(2-oxo-6-phenyl-2H-pyran-4-yl)-L-leucinamide 

Relevant academic research and scientific papers

Arylamine based cathepsin K inhibitors: Investigating P3 heterocyclic substituents

A modification of novel cathepsin K inhibitors I was carried out. The structural design was aimed at reducing the lipophilic character of compounds I for obtaining better pharmacokinetic profiles. This modification afforded several less lipophilic compoun